6.
Papanikolaou E, Bosio A
. The Promise and the Hope of Gene Therapy. Front Genome Ed. 2021; 3:618346.
PMC: 8525363.
DOI: 10.3389/fgeed.2021.618346.
View
7.
McElree I, Steinberg R, Mott S, ODonnell M, Packiam V
. Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer. JAMA Netw Open. 2023; 6(2):e230849.
PMC: 9975907.
DOI: 10.1001/jamanetworkopen.2023.0849.
View
8.
Wust P, Hildebrandt B, Sreenivasa G, Rau B, Gellermann J, Riess H
. Hyperthermia in combined treatment of cancer. Lancet Oncol. 2002; 3(8):487-97.
DOI: 10.1016/s1470-2045(02)00818-5.
View
9.
Sun B, Rahmat J, Kim H, Mahendran R, Esuvaranathan K, Chiong E
. Wirelessly Activated Nanotherapeutics for In Vivo Programmable Photodynamic-Chemotherapy of Orthotopic Bladder Cancer. Adv Sci (Weinh). 2022; 9(16):e2200731.
PMC: 9165499.
DOI: 10.1002/advs.202200731.
View
10.
Rieckmann T, Kotevic I, Trueb B
. The cell surface receptor FGFRL1 forms constitutive dimers that promote cell adhesion. Exp Cell Res. 2007; 314(5):1071-81.
DOI: 10.1016/j.yexcr.2007.10.029.
View
11.
Shore N, Boorjian S, Canter D, Ogan K, Karsh L, Downs T
. Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol. 2017; 35(30):3410-3416.
PMC: 5648171.
DOI: 10.1200/JCO.2017.72.3064.
View
12.
Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L
. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2006; 66(6 Suppl 1):4-34.
DOI: 10.1016/j.urology.2005.07.062.
View
13.
Guo P, Shang W, Peng L, Wang L, Wang H, Han Z
. A gel system for single instillation of non-muscle-invasive bladder Cancer: A "divide-and-rule" strategy. J Control Release. 2018; 285:46-55.
DOI: 10.1016/j.jconrel.2018.06.036.
View
14.
Li R, Tabayoyong W, Guo C, Nogueras Gonzalez G, Navai N, Grossman H
. Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease. Eur Urol. 2018; 75(1):8-10.
DOI: 10.1016/j.eururo.2018.09.028.
View
15.
Tan W, Longo T, Inman B
. Heated Intravesical Chemotherapy: Biology and Clinical Utility. Urol Clin North Am. 2019; 47(1):55-72.
PMC: 6917042.
DOI: 10.1016/j.ucl.2019.09.008.
View
16.
Zhang S, Yu Y, Zhang Y, Qu W, Li J
. Radiotherapy in muscle-invasive bladder cancer: the latest research progress and clinical application. Am J Cancer Res. 2015; 5(2):854-68.
PMC: 4396032.
View
17.
Steinberg R, Thomas L, Brooks N, Mott S, Vitale A, Crump T
. Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer. J Urol. 2019; 203(5):902-909.
DOI: 10.1097/JU.0000000000000688.
View
18.
Zhang S, Sun C, Zeng J, Sun Q, Wang G, Wang Y
. Ambient Aqueous Synthesis of Ultrasmall PEGylated Cu Se Nanoparticles as a Multifunctional Theranostic Agent for Multimodal Imaging Guided Photothermal Therapy of Cancer. Adv Mater. 2016; 28(40):8927-8936.
DOI: 10.1002/adma.201602193.
View
19.
Oliveira M, Villa Nova M, Bruschi M
. A review of recent developments on micro/nanostructured pharmaceutical systems for intravesical therapy of the bladder cancer. Pharm Dev Technol. 2017; 23(1):1-12.
DOI: 10.1080/10837450.2017.1312441.
View
20.
Tey J, Soon Y, Cheo T, Ooi K, Ho F, Vellayappan B
. Efficacy of Palliative Bladder Radiotherapy for Hematuria in Advanced Bladder Cancer Using Contemporary Radiotherapy Techniques. In Vivo. 2019; 33(6):2161-2167.
PMC: 6899121.
DOI: 10.21873/invivo.11718.
View